Piramal Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 07-07-2024
- Paid Up Capital ₹ 0.40 M
as on 07-07-2024
- Company Age 12 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -14.62%
(FY 2022)
- Profit -24.20%
(FY 2022)
- Ebitda 83.12%
(FY 2022)
- Net Worth 1.28%
(FY 2022)
- Total Assets 1.11%
(FY 2022)
About Piramal Biotech
The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.40 M, as per Ministry of Corporate Affairs (MCA) records.
Vandana Chablani and Kshitish Bapat serve as directors at the Company.
- CIN/LLPIN
U74120MH2012PTC234739
- Company No.
234739
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Aug 2012
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Piramal Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vandana Chablani  | Director | 01-Aug-2014 | Current |
| Kshitish Bapat | Additional Director | Current |
Financial Performance and Corporate Structure Insights of Piramal Biotech.
Piramal Biotech Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 14.62% decrease. The company also saw a substantial fall in profitability, with a 24.2% decrease in profit. The company's net worth moved up by a moderate rise of 1.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Piramal Biotech?
In 2021, Piramal Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Piramal Trusteeship Services Private LimitedActive 7 years 7 monthsVandana Chablani is a mutual person
- Piramal Retail Private LimitedActive 12 years 9 months
Vandana Chablani and Kshitish Bapat are mutual person
- Piramal Natural Resources Private LimitedActive 12 years 5 months
Vandana Chablani is a mutual person
- Piramal International Consultants Private LimitedActive 12 years 4 months
Vandana Chablani and Kshitish Bapat are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Piramal Biotech?
Unlock and access historical data on people associated with Piramal Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Piramal Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Piramal Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
